10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELEVANCE HEALTH, INC. | |||
Ticker: ELV Fiscal Year: 2015 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 19, 2016) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Operating activities | |||
| Net income | $ 2,560,000 | 2,569,700 | 2,489,700 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Net realized gains on investments | (157,500) | (177,000) | (271,900) |
| Other-than-temporary impairment losses recognized in income | 83,400 | 49,000 | 98,900 |
| (Gain) loss on extinguishment of debt | (9,300) | 81,100 | 145,300 |
| (Gain) loss on disposal from discontinued operations | 0 | (3,200) | 221,800 |
| Loss (gain) on disposal of assets | 16,000 | (1,700) | 3,900 |
| Deferred income taxes | (65,900) | 30,700 | 59,100 |
| Amortization, net of accretion | 802,100 | 744,500 | 800,900 |
| Depreciation expense | 105,800 | 106,500 | 107,900 |
| Impairment of property and equipment | 1,800 | 7,900 | 47,700 |
| Share-based compensation | 148,200 | 168,900 | 146,000 |
| Excess tax benefits from share-based compensation | (95,800) | (46,400) | (30,100) |
| Changes in operating assets and liabilities: | |||
| Receivables, net | (42,900) | (1,899,700) | (418,300) |
| Other invested assets | 5,900 | (21,700) | (15,100) |
| Other assets | 33,800 | 405,500 | (33,600) |
| Policy liabilities | 193,000 | 1,240,600 | (345,800) |
| Unearned income | 33,900 | 255,100 | (73,800) |
| Accounts payable and accrued expenses | (219,300) | (14,400) | 303,600 |
| Other liabilities | 686,400 | (7,900) | (154,600) |
| Income taxes | 41,500 | (34,000) | 9,300 |
| Other, net | (5,100) | (84,200) | (38,600) |
| Net cash provided by operating activities | 4,116,000 | 3,369,300 | 3,052,300 |
| Investing activities | |||
| Purchases of fixed maturity securities | (9,792,000) | (9,613,400) | (13,704,500) |
| Proceeds from fixed maturity securities: | |||
| Sales | 8,909,200 | 8,066,000 | 10,977,900 |
| Maturities, calls and redemptions | 1,313,600 | 1,318,700 | 1,836,800 |
| Purchases of equity securities | (1,561,400) | (912,000) | (820,300) |
| Proceeds from sales of equity securities | 1,471,100 | 746,500 | 721,000 |
| Purchases of other invested assets | (505,800) | (205,700) | (251,500) |
| Proceeds from sales of other invested assets | 85,900 | 124,700 | 127,100 |
| Settlement of non-hedging derivatives | (36,500) | (67,400) | (109,800) |
| Changes in securities lending collateral | 214,400 | (545,600) | (405,100) |
| Purchases of subsidiaries, net of cash acquired | (638,900) | 0 | 0 |
| Proceeds from sale of subsidiary, net of cash sold | 0 | 740,000 | 0 |
| Purchases of property and equipment | (638,200) | (714,600) | (646,500) |
| Proceeds from sales of property and equipment | 35,300 | 88,000 | 39,200 |
| Other, net | (8,200) | (100) | 1,300 |
| Net cash used in investing activities | (1,151,500) | (974,900) | (2,234,400) |
| Financing activities | |||
| Net proceeds from (repayments of) commercial paper borrowings | 682,200 | (379,200) | (191,700) |
| Proceeds from long-term borrowings | 1,226,500 | 2,700,000 | 1,250,000 |
| Repayments of long-term borrowings | (2,697,200) | (1,730,100) | (1,801,900) |
| Proceeds from short-term borrowings | 2,760,000 | 2,050,000 | 1,100,000 |
| Repayments of short-term borrowings | (2,620,000) | (2,050,000) | (950,000) |
| Changes in securities lending payable | (214,400) | 545,600 | 405,000 |
| Changes in bank overdrafts | (243,800) | 173,000 | 9,900 |
| Premiums paid on equity call options | (16,700) | 0 | (25,800) |
| Proceeds from sale of put options | 16,600 | 0 | 0 |
| Repurchase and retirement of common stock | (1,515,800) | (2,998,800) | (1,620,100) |
| Cash dividends | (656,600) | (480,700) | (448,000) |
| Proceeds from issuance of common stock under employee stock plans | 186,000 | 301,300 | 524,700 |
| Excess tax benefits from share-based compensation | 95,800 | 46,400 | 30,100 |
| Net cash used in financing activities | (2,997,400) | (1,822,500) | (1,717,800) |
| Effect of foreign exchange rates on cash and cash equivalents | (5,300) | (7,100) | 2,200 |
| Change in cash and cash equivalents | (38,200) | 564,800 | (897,700) |
| Cash and cash equivalents at beginning of year | 2,151,700 | 1,586,900 | |
| Cash and cash equivalents at end of year | 2,113,500 | 2,151,700 | 1,586,900 |
| Less cash and cash equivalents of discontinued operations at year end | 0 | 0 | (4,800) |
| Cash and cash equivalents of continuing operations at end of year | 2,113,500 | 2,151,700 | 1,582,100 |
| External Links | |
| ELEVANCE HEALTH, INC. (ELV) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |